Drug may reduce post-menopausal breast cancer risks
Jun 6, 2011
New findings from the Massachusetts General Hospital Cancer Center show that Aromasin, also known as Exemestane, is a breast cancer drug that can decrease the risks of tumor development in post-menopausal women, according to a recent report from the Los Angeles Times.
"Breast cancer is the second-most-common cause of death from cancer in women and one of the most feared diagnoses for women in the United States," wrote Drs. Nancy E. Davidson and Thomas W. Kensler of the University of Pittsburgh Cancer Institute. "We have the knowledge and tools to reduce its incidence today. We have run out of excuses. What are we waiting for?"
The findings were presented in the New England Journal of Medicine, as well as at the American Society of Clinical Oncology meeting in Chicago.
Breast cancer affects one out of every eight women in the U.S., according to the American Cancer Society. More than 200,000 women were newly diagnosed with the illness last year and the disease is more common in older women.